{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:27:20Z","timestamp":1767713240804},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41431-017-0057-3","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:25:59Z","timestamp":1522362359000},"page":"972-983","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history"],"prefix":"10.1038","volume":"26","author":[{"name":"for the TFGT Collaborative Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Meiser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica F.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaaren J.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Peate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christobel","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Geelhoed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Barlow-Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoland C.","family":"Antill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Susman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llew","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"57_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrclinonc.2010.175","volume":"7","author":"A Trainer","year":"2010","unstructured":"Trainer A, Lewis C, Tucker K, Meiser B, Friedlander M, Ward R. Treatment-focused genetic assessment in breast cancer - the evolving role of the familial cancer services. Nat Rev Clin Oncol. 2010;7:708\u201317.","journal-title":"Nat Rev Clin Oncol"},{"key":"57_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10549-010-1336-7","volume":"127","author":"K Metcalfe","year":"2011","unstructured":"Metcalfe K, Lynch H, Ghadirian P, et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Tr. 2011;127:287\u201396.","journal-title":"Breast Cancer Res Tr"},{"key":"57_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","volume":"34","author":"A Broek van den","year":"2015","unstructured":"van den Broek A, van\u2019t Veer L, Hooning M, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers. J Clin Oncol. 2015;34:409\u201318.","journal-title":"J Clin Oncol"},{"key":"57_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/bmj.g226","volume":"348","author":"K Metcalfe","year":"2014","unstructured":"Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:226.","journal-title":"BMJ"},{"key":"57_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","volume":"140","author":"D Evans","year":"2013","unstructured":"Evans D, Ingham S, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135\u201342.","journal-title":"Breast Cancer Res Treat"},{"key":"57_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"T Rebbeck","year":"2009","unstructured":"Rebbeck T, Kauff N, Domchek S, Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"57_CR7","first-page":"djw177","volume":"109","author":"J Kotsopoulos","year":"2017","unstructured":"Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral oophorectomy and breastcancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017;109:djw177","journal-title":"J Natl Cancer Inst"},{"key":"57_CR8","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","volume":"33","author":"M Telli","year":"2015","unstructured":"Telli M, Jensen K, Vinayak S, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation\u2013associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33:1895\u2013901.","journal-title":"J Clin Oncol"},{"key":"57_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","volume":"43","author":"P Moller","year":"2007","unstructured":"Moller P, Hagen A, Apold J, et al. Genetic epidemiology of BRCA mutations - family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007;43:1713\u20137.","journal-title":"Eur J Cancer"},{"key":"57_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc2054","volume":"7","author":"J Fackenthal","year":"2007","unstructured":"Fackenthal J, Olopade O. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7:937\u201348.","journal-title":"Nat Rev Cancer"},{"key":"57_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/gim.2014.134","volume":"17","author":"A Bradbury","year":"2015","unstructured":"Bradbury A, Patrick-Miller L, Long J, et al. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2015;17:485\u201392.","journal-title":"Genet Med"},{"key":"57_CR12","first-page":"CD003721","volume":"2","author":"J Hilgart","year":"2012","unstructured":"Hilgart J, Coles B, Iredale R. Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev. 2012;2:CD003721.","journal-title":"Cochrane Database Syst Rev"},{"key":"57_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1037\/a0014778","volume":"28","author":"JG Hamilton","year":"2009","unstructured":"Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: A meta-analytic review. Health Psychol. 2009;28:510\u20138.","journal-title":"Health Psychol"},{"key":"57_CR14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ejca.2006.05.032","volume":"42","author":"KJ Schlich-Bakker","year":"2006","unstructured":"Schlich-Bakker KJ, Warlam-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42: 2722\u20138.","journal-title":"Eur J Cancer"},{"key":"57_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-007-9680-y","volume":"109","author":"KJ Schlich-Bakker","year":"2008","unstructured":"Schlich-Bakker KJ, Ausems MG, Schipper M, Ten Kroode HF, Warlam-Rodenhuis CC, BRCA1\/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat. 2008;109:507\u201314.","journal-title":"Breast Cancer Res Treat"},{"key":"57_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/gim.2012.31","volume":"14","author":"S Shkedi-Rafid","year":"2012","unstructured":"Shkedi-Rafid S, Gabai-Kapara E, Grinshpun-Cohen J, Levy-Lahad E. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening. Genet Med. 2012;14:688\u201394.","journal-title":"Genet Med"},{"key":"57_CR17","first-page":"379","volume":"107","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish Community: a randomized controlled trial. J Natl Cancer Inst. 2015;107:379.","journal-title":"J Natl Cancer Inst"},{"key":"57_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/bmj.316.7132.693","volume":"316","author":"TM Marteau","year":"1998","unstructured":"Marteau TM, Croyle RT. Psychological responses to genetic testing. Br Med J. 1998;316:693\u20136.","journal-title":"Br Med J"},{"key":"57_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-320","volume":"12","author":"K Watts","year":"2012","unstructured":"Watts K, Meiser B, Mitchell G, et al. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer. 2012;12:320.","journal-title":"BMC Cancer"},{"key":"57_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/gim.2016.130","volume":"19","author":"V Quinn","year":"2017","unstructured":"Quinn V, Meiser B, Kirk J, et al. Streamlined education is effective for women newly diagnosed with breast cancer considering genetic testing. Genet Med. 2017;19:448\u201356.","journal-title":"Genet Med"},{"key":"57_CR21","volume-title":"Advice about familial aspects of breast cancer and epithelial ovarian cancer: A guide for health professionals","author":"National Breast Cancer Centre.","year":"2010","unstructured":"National Breast Cancer Centre. Advice about familial aspects of breast cancer and epithelial ovarian cancer: A guide for health professionals. Sydney: NHMRC National Breast and Ovarian Cancer Centre; 2010."},{"key":"57_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pon.533","volume":"10","author":"B Thewes","year":"2001","unstructured":"Thewes B, Meiser B, Hickie I. Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psycho-Oncol. 2001;10:459\u201368.","journal-title":"Psycho-Oncol"},{"key":"57_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0959-8049(05)80015-2","volume":"30A","author":"T Ibbotson","year":"1994","unstructured":"Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L. Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer. 1994;30A:37\u201340.","journal-title":"Eur J Cancer"},{"key":"57_CR24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1037\/0278-6133.21.6.564","volume":"21","author":"D Cella","year":"2002","unstructured":"Cella D, Chang C, Peterman A, et al. A brief assessment of concerns associated with genetic testing for cancer: The multidimensional impact of cancer risk assessment (MICRA) questionnaire. Health Psychol. 2002;21:564\u201372.","journal-title":"Health Psychol"},{"key":"57_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0272989X03256005","volume":"23","author":"JC Brehaut","year":"2003","unstructured":"Brehaut JC, O\u2019Connor AM, Wood TJ, et al. Validation of a decision regret scale. Med Dec Mak. 2003;23:281\u201392.","journal-title":"Med Dec Mak"},{"key":"57_CR26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMsr1613680","volume":"376","author":"D Lannin","year":"2017","unstructured":"Lannin D, Wang S. Are small breast cancers good because they are small or small because they are good? N Engl J Med. 2017;376:2286\u201391.","journal-title":"N Engl J Med"},{"key":"57_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001","volume-title":"Applied longitudinal data analysis: Modeling change and event occurrence","author":"J Singer","year":"2003","unstructured":"Singer J, Willett J. Applied longitudinal data analysis: Modeling change and event occurrence. New York: Oxford University Press; 2003."},{"key":"57_CR28","unstructured":"Cancer Australia. Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation. in: Australia C, editor. A clinical practive guideline. Canberra: Cancer Australia; 2014."},{"key":"57_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/ejhg.2016.69","volume":"24","author":"B Meiser","year":"2016","unstructured":"Meiser B, Quinn V, Gleeson M, et al. When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer. Eur J Hum Genet. 2016;24:1571\u20131523.","journal-title":"Eur J Hum Genet"},{"key":"57_CR30","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1200\/JCO.2004.04.086","volume":"22","author":"M Schwartz","year":"2004","unstructured":"Schwartz M, Lerman C, Brogan B, et al. Impact of BRCA1\/2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823\u20139.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41431-017-0057-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-017-0057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-017-0057-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:41:39Z","timestamp":1684618899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-017-0057-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1038\/s41431-017-0057-3","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"type":"print","value":"1018-4813"},{"type":"electronic","value":"1476-5438"}],"subject":[],"published":{"date-parts":[[2018,3,30]]},"assertion":[{"value":"11 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BM, KT and MG have remunerated consultant roles with the company Astrazeneca with respect to unrelated projects. The remaining authors declare that they have no competing intersts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}